Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.

Ilic K, Hawke RL, Thirumaran RK, Schuetz EG, Hull JH, Kashuba AD, Stewart PW, Lindley CM, Chen ML.

Drug Metab Dispos. 2013 Mar;41(3):575-81. doi: 10.1124/dmd.112.048108. Epub 2012 Dec 13.

2.

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.

Dees EC, O'Neil BH, Lindley CM, Collichio F, Carey LA, Collins J, Riordan WJ, Ivanova A, Esseltine D, Orlowski RZ.

Cancer Chemother Pharmacol. 2008 Dec;63(1):99-107. doi: 10.1007/s00280-008-0716-8. Epub 2008 Mar 8.

3.

Nelarabine: a novel purine antimetabolite antineoplastic agent.

Buie LW, Epstein SS, Lindley CM.

Clin Ther. 2007 Sep;29(9):1887-99. Review.

PMID:
18035189
4.

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects.

Hogeland GW, Swindells S, McNabb JC, Kashuba AD, Yee GC, Lindley CM.

Clin Pharmacol Ther. 2007 Jan;81(1):69-75.

PMID:
17186001
5.

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC.

Blood. 2005 Apr 15;105(8):3058-65. Epub 2004 Dec 30.

6.

First reported prairie dog-to-human tularemia transmission, Texas, 2002.

Avashia SB, Petersen JM, Lindley CM, Schriefer ME, Gage KL, Cetron M, DeMarcus TA, Kim DK, Buck J, Montenieri JA, Lowell JL, Antolin MF, Kosoy MY, Carter LG, Chu MC, Hendricks KA, Dennis DT, Kool JL.

Emerg Infect Dis. 2004 Mar;10(3):483-6.

7.

Patient-specific factors affecting patient-controlled analgesia dosing.

Glasson JC, Sawyer WT, Lindley CM, Ginsberg B.

J Pain Palliat Care Pharmacother. 2002;16(2):5-21.

PMID:
14650457
8.

Evaluation of the contribution of cytochrome P450 3A4 to human liver microsomal bupropion hydroxylation.

Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM.

Drug Metab Dispos. 2001 Aug;29(8):1123-9.

PMID:
11454731
9.

Evaluation of outcomes in converting from intravenous ondansetron to oral granisetron: an observational study.

McCune JS, Oertel MD, Pfeifer D, Houston SA, Bingham A, Sawyer WT, Lindley CM.

Ann Pharmacother. 2001 Jan;35(1):14-20.

PMID:
11197579
10.

Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Faucette SR, Hawke RL, Lecluyse EL, Shord SS, Yan B, Laethem RM, Lindley CM.

Drug Metab Dispos. 2000 Oct;28(10):1222-30.

PMID:
10997944
11.

Coagulation products and their uses.

Shord SS, Lindley CM.

Am J Health Syst Pharm. 2000 Aug 1;57(15):1403-17; quiz 1418-20. Review.

PMID:
10938981
12.

Granulocyte colony-stimulating factor use in cancer patients.

Baker J, McCune JS, Harvey RD 3rd, Bonsignore C, Lindley CM.

Ann Pharmacother. 2000 Jul-Aug;34(7-8):851-7.

PMID:
10928394
13.

Cancer pain survey: patient-centered issues in control.

Thomason TE, McCune JS, Bernard SA, Winer EP, Tremont S, Lindley CM.

J Pain Symptom Manage. 1998 May;15(5):275-84.

PMID:
9654832
14.

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.

Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM.

Haemophilia. 1997 Jul;3(3):231. doi: 10.1046/j.1365-2516.1997.t01-1-00125.x. No abstract available.

PMID:
27214818
15.

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.

Liles D, Landen CN, Monroe DM, Lindley CM, Read MS, Roberts HR, Brinkhous KM.

Thromb Haemost. 1997 May;77(5):944-8.

PMID:
9184407
16.

Proposal for classifying the acute emetogenicity of cancer chemotherapy.

Hesketh PJ, Kris MG, Grunberg SM, Beck T, Hainsworth JD, Harker G, Aapro MS, Gandara D, Lindley CM.

J Clin Oncol. 1997 Jan;15(1):103-9. Review.

PMID:
8996130
17.

Task analysis of home care pharmacy.

Bemus AM, Lindley CM, Sawyer WT, McAllister JC 3rd.

Am J Health Syst Pharm. 1996 Dec 1;53(23):2831-9.

PMID:
8957343
18.

Methotrexate elimination in a patient with an orthotopic neobladder with and without a urethral catheter.

Wire PD, Dupuis RE, Mohler JL, Bernard SA, Lindley CM.

Pharmacotherapy. 1996 Sep-Oct;16(5):961-4.

PMID:
8888094
19.

Pharmacy-perceived barriers to cancer pain control: results of the North Carolina Cancer Pain Initiative Pharmacist Survey.

Krick SE, Lindley CM, Bennett M.

Ann Pharmacother. 1994 Jul-Aug;28(7-8):857-62.

PMID:
7949500
20.

Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.

Lindley CM, Sawyer WT, Macik BG, Lusher J, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR.

Clin Pharmacol Ther. 1994 Jun;55(6):638-48.

PMID:
8004880
21.

Oncology nurses' attitudes, perceptions, and knowledge of quality-of-life assessment in patients with cancer.

Lindley CM, Hirsch JD.

Oncol Nurs Forum. 1994 Jan-Feb;21(1):103-8; discussion 108-10.

PMID:
8139993
22.

Assessment of pain and patterns of analgesic use in hospice patients.

Morgan AE, Lindley CM, Berry JI.

Am J Hosp Palliat Care. 1994 Jan-Feb;11(1):13-9, 22-5.

PMID:
8117486
23.

Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.

Macik BG, Lindley CM, Lusher J, Sawyer WT, Bloom AL, Harrison JF, Baird-Cox K, Birch K, Glazer S, Roberts HR.

Blood Coagul Fibrinolysis. 1993 Aug;4(4):521-7.

PMID:
8218848
24.
25.

Quality of life consequences of chemotherapy-induced emesis.

Lindley CM, Hirsch JD, O'Neill CV, Transau MC, Gilbert CS, Osterhaus JT.

Qual Life Res. 1992 Oct;1(5):331-40.

PMID:
1299465
26.

Inappropriate medication is a major cause of adverse drug reactions in elderly patients.

Lindley CM, Tully MP, Paramsothy V, Tallis RC.

Age Ageing. 1992 Jul;21(4):294-300.

PMID:
1514459
27.

Cisplatin-based chemotherapy in a renal transplant recipient.

Lindley CM, Gordon TR, Tremont SJ.

Cancer. 1991 Sep 1;68(5):1113-7. Review.

PMID:
1913483
28.

Vomiting associated with pentostatin and pentostatin plus alpha-interferon: unique pattern and potential mechanisms.

Lindley CM, Bernard SA, Robertson JD.

J Pain Symptom Manage. 1990 Aug;5(4):262-4.

PMID:
2384706
29.

Narcotic analgesics. Clinical pharmacology and therapeutics.

Lindley CM, Dalton JA, Fields SM.

Cancer Nurs. 1990 Feb;13(1):28-38. Review.

PMID:
2407339
30.

Role of angiotensin II and vasopressin in cisplatin-induced emesis.

Cubeddu LX, Lindley CM, Wetsel W, Carl PL, Negro-Vilar A.

Life Sci. 1990;46(10):699-705.

PMID:
2314191
31.

Incidence and duration of chemotherapy-induced nausea and vomiting in the outpatient oncology population.

Lindley CM, Bernard S, Fields SM.

J Clin Oncol. 1989 Aug;7(8):1142-9.

PMID:
2787840
32.

Thrombotic microangiopathy associated with chemotherapy: case report and review of the literature.

Fields SM, Lindley CM.

DICP. 1989 Jul-Aug;23(7-8):582-8. Review.

PMID:
2669373
33.

Extreme warfarin intoxication secondary to possible covert drug ingestion.

Richmond RG, Sawyer WT, Aiello PD, Lindley CM.

Drug Intell Clin Pharm. 1988 Sep;22(9):696-9.

PMID:
3215113
34.

Cancer detection and therapeutics.

Lindley CM.

Am Pharm. 1988 Apr;NS28(4):24. No abstract available.

PMID:
3369351
35.

Skin cancers: detection, prevention, and therapeutics.

Lindley CM, Cronquist SE.

Am Pharm. 1988 Apr;NS28(4):32-41. Review. No abstract available.

PMID:
3285657
36.

Two-pharmacist marriages. Lindley and McAllister.

Lindley CM, McAllister JC 3rd.

Am J Hosp Pharm. 1987 Dec;44(12):2719-21. No abstract available.

PMID:
3434578
37.

Effectiveness of improved targeting efforts for influenza immunization in an ambulatory care setting.

Williams DM, Daugherty LM, Aycock DG, Lindley CM, Harris MJ.

Hosp Pharm. 1987 May;22(5):462-4.

PMID:
10282251
38.

Strategies for program planning, implementation and control.

McAllister JC 3rd, Lindley CM.

Top Hosp Pharm Manage. 1983 May;3(1):72-83. No abstract available.

PMID:
10314008

Supplemental Content

Loading ...
Support Center